BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 30981008)

  • 1. Development and Validation of the Mucosal Inflammation Noninvasive Index For Pediatric Crohn's Disease.
    Cozijnsen MA; Ben Shoham A; Kang B; Choe BH; Choe YH; Jongsma MME; Russell RK; Ruemmele FM; Escher JC; de Ridder L; Koletzko S; Martín-de-Carpi J; Hyams J; Walters T; Griffiths A; Turner D
    Clin Gastroenterol Hepatol; 2020 Jan; 18(1):133-140.e1. PubMed ID: 30981008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations Among Mucosal and Transmural Healing and Fecal Level of Calprotectin in Children With Crohn's Disease.
    Weinstein-Nakar I; Focht G; Church P; Walters TD; Abitbol G; Anupindi S; Berteloot L; Hulst JM; Ruemmele F; Lemberg DA; Leach ST; Cytter R; Greer ML; Griffiths AM; Turner D;
    Clin Gastroenterol Hepatol; 2018 Jul; 16(7):1089-1097.e4. PubMed ID: 29501599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting Endoscopic Crohn's Disease Activity Before and After Induction Therapy in Children: A Comprehensive Assessment of PCDAI, CRP, and Fecal Calprotectin.
    Zubin G; Peter L
    Inflamm Bowel Dis; 2015 Jun; 21(6):1386-91. PubMed ID: 25851564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Noninvasive Fecal Immunochemical Testing and Fecal Calprotectin Predict Mucosal Healing in Inflammatory Bowel Disease: A Prospective Cohort Study.
    Ma C; Lumb R; Walker EV; Foshaug RR; Dang TT; Verma S; Huang VW; Kroeker KI; Wong K; Dieleman LA; Fedorak RN; Halloran BP
    Inflamm Bowel Dis; 2017 Sep; 23(9):1643-1649. PubMed ID: 28644184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Which PCDAI Version Best Reflects Intestinal Inflammation in Pediatric Crohn Disease?
    Turner D; Levine A; Walters TD; Focht G; Otley A; López VN; Koletzko S; Baldassano R; Mack D; Hyams J; Griffiths AM
    J Pediatr Gastroenterol Nutr; 2017 Feb; 64(2):254-260. PubMed ID: 27050050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
    D'Haens G; Ferrante M; Vermeire S; Baert F; Noman M; Moortgat L; Geens P; Iwens D; Aerden I; Van Assche G; Van Olmen G; Rutgeerts P
    Inflamm Bowel Dis; 2012 Dec; 18(12):2218-24. PubMed ID: 22344983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and Validation of a Test to Monitor Endoscopic Activity in Patients With Crohn's Disease Based on Serum Levels of Proteins.
    D'Haens G; Kelly O; Battat R; Silverberg MS; Laharie D; Louis E; Savarino E; Bodini G; Yarur A; Boland BS; Afif W; Li XJ; Hale M; Ho J; Kondragunta V; Huang B; Kuy C; Okada L; Hester KD; Bray KR; Mimms L; Jain A; Singh S; Collins A; Valasek MA; Sandborn WJ; Vermeire S; Dulai PS
    Gastroenterology; 2020 Feb; 158(3):515-526.e10. PubMed ID: 31711925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Level of Fecal Calprotectin Correlates With Severity of Small Bowel Crohn's Disease, Measured by Balloon-assisted Enteroscopy and Computed Tomography Enterography.
    Arai T; Takeuchi K; Miyamura M; Ishikawa R; Yamada A; Katsumata M; Igarashi Y; Suzuki Y
    Clin Gastroenterol Hepatol; 2017 Jan; 15(1):56-62. PubMed ID: 27565523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of video capsule endoscopy for longitudinal monitoring of Crohn's disease activity in the small bowel: a prospective study.
    Melmed GY; Dubinsky MC; Rubin DT; Fleisher M; Pasha SF; Sakuraba A; Tiongco F; Shafran I; Fernandez-Urien I; Rosa B; Papageorgiou NP; Leighton JA
    Gastrointest Endosc; 2018 Dec; 88(6):947-955.e2. PubMed ID: 30086261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease.
    Kostas A; Siakavellas SI; Kosmidis C; Takou A; Nikou J; Maropoulos G; Vlachogiannakos J; Papatheodoridis GV; Papaconstantinou I; Bamias G
    World J Gastroenterol; 2017 Nov; 23(41):7387-7396. PubMed ID: 29151692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Both fecal calprotectin and fecal immunochemical tests are useful in children with inflammatory bowel disease.
    Shimizu H; Ebana R; Kudo T; Sato T; Hara T; Hosoi K; Usami M; Yoshida M; Takeuchi I; Nakase H; Iwama I; Arai K; Shimizu T
    J Gastroenterol; 2022 May; 57(5):344-356. PubMed ID: 35165800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China.
    Chen JM; Liu T; Gao S; Tong XD; Deng FH; Nie B
    World J Gastroenterol; 2017 Dec; 23(46):8235-8247. PubMed ID: 29290660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Magnetic resonance enterography, colonoscopy, and fecal calprotectin correlate in colonic Crohn's disease.
    Somwaru AS; Khanijow V; Katabathina VS
    BMC Gastroenterol; 2019 Dec; 19(1):210. PubMed ID: 31805875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic Review and External Validation of Prediction Models Based on Symptoms and Biomarkers for Identifying Endoscopic Activity in Crohn's Disease.
    Brand EC; Elias SG; Minderhoud IM; van der Veen JJ; Baert FJ; Laharie D; Bossuyt P; Bouhnik Y; Buisson A; Lambrecht G; Louis E; Pariente B; Pierik MJ; van der Woude CJ; D'Haens GRAM; Vermeire S; Oldenburg B;
    Clin Gastroenterol Hepatol; 2020 Jul; 18(8):1704-1718. PubMed ID: 31881273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of disease activity of Crohn's disease through fecal calprotectin evaluated by balloon-assisted endoscopy.
    Iwamoto F; Matsuoka K; Motobayashi M; Takenaka K; Kuno T; Tanaka K; Tsukui Y; Kobayashi S; Yoshida T; Fujii T; Saito E; Yamaguchi T; Nagahori M; Sato T; Ohtsuka K; Enomoto N; Watanabe M
    J Gastroenterol Hepatol; 2018 Dec; 33(12):1984-1989. PubMed ID: 29889986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between Fecal Calprotectin and Mucosal Healing in Pediatric Patients with Crohn's Disease Who Have Achieved Sustained Clinical Remission with Anti-Tumor Necrosis Factor Agents.
    Lee YM; Choi S; Choe BH; Jang HJ; Kim S; Koh H; Kim ES; Kim MJ; Choe YH; Kang B
    Gut Liver; 2022 Jan; 16(1):62-70. PubMed ID: 33833135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association Between Level of Fecal Calprotectin and Progression of Crohn's Disease.
    Kennedy NA; Jones GR; Plevris N; Patenden R; Arnott ID; Lees CW
    Clin Gastroenterol Hepatol; 2019 Oct; 17(11):2269-2276.e4. PubMed ID: 30772585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fecal Immunochemical Test Versus Fecal Calprotectin for Prediction of Mucosal Healing in Crohn's Disease.
    Inokuchi T; Kato J; Hiraoka S; Takashima S; Nakarai A; Takei D; Sugihara Y; Takahara M; Kawano S; Harada K; Okada H
    Inflamm Bowel Dis; 2016 May; 22(5):1078-85. PubMed ID: 26891256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid fecal calprotectin test for prediction of mucosal inflammation in ulcerative colitis and Crohn disease: a prospective cohort study.
    Moniuszko A; Głuszek S; Rydzewska G
    Pol Arch Intern Med; 2017 May; 127(5):312-318. PubMed ID: 28442699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fecal HMGB1 Reveals Microscopic Inflammation in Adult and Pediatric Patients with Inflammatory Bowel Disease in Clinical and Endoscopic Remission.
    Palone F; Vitali R; Cucchiara S; Mennini M; Armuzzi A; Pugliese D; DʼIncà R; Barberio B; Stronati L
    Inflamm Bowel Dis; 2016 Dec; 22(12):2886-2893. PubMed ID: 27755215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.